Search research articles
Contact Us
Filters
Showing results (501-510 of 514) with videos related to
Page
of 52
Sort By:
Pigment Cell & Melanoma Research
|
May 1, 2012
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines
Craig Carson, Bernard Omolo, Haitao Chu, et al.
Pharmacogenetics and Genomics
|
September 7, 2017
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment
Lauren A Marcath, Allison M Deal, Emily Van Wieren, et al.
Scientific Reports
|
June 7, 2016
An Automated High-throughput Array Microscope for Cancer Cell Mechanics
Jeremy A Cribb, Lukas D Osborne, Kellie Beicker, et al.
Veterinary Sciences
|
February 26, 2026
Antiparasitic Activity of <i>Hedera helix</i> Extract-Loaded Chitosan Nanoparticles in Experimentally Induced Giardiasis
Hany M El-Wahsh, Faten Abdullah Al Braikan, Doaa Naguib, et al.
The Journal of Investigative Dermatology
|
June 29, 2007
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression
William K Kaufmann, Kathleen R Nevis, Pingping Qu, et al.
Journal of the National Cancer Institute
|
April 1, 2014
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer
Hanna K Sanoff, Allison M Deal, Janakiraman Krishnamurthy, et al.
Public Health Genomics
|
January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer
N T Brewer, J T Defrank, W K Chiu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
Benjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
British Journal of Clinical Pharmacology
|
April 25, 2015
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
Daniel L Hertz, Anna C Snavely, Howard L McLeod, et al.
The Oncologist
|
May 27, 2016
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Daniel L Hertz, Allison Deal, Joseph G Ibrahim, et al.
Page
of 52
Search research articles
Search
Showing results (501-510 of 514) with videos related to
Sort By:
Page
of 52
Pigment Cell & Melanoma Research
|
May 1, 2012
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines
Craig Carson, Bernard Omolo, Haitao Chu, et al.
Pharmacogenetics and Genomics
|
September 7, 2017
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment
Lauren A Marcath, Allison M Deal, Emily Van Wieren, et al.
Scientific Reports
|
June 7, 2016
An Automated High-throughput Array Microscope for Cancer Cell Mechanics
Jeremy A Cribb, Lukas D Osborne, Kellie Beicker, et al.
Veterinary Sciences
|
February 26, 2026
Antiparasitic Activity of <i>Hedera helix</i> Extract-Loaded Chitosan Nanoparticles in Experimentally Induced Giardiasis
Hany M El-Wahsh, Faten Abdullah Al Braikan, Doaa Naguib, et al.
The Journal of Investigative Dermatology
|
June 29, 2007
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression
William K Kaufmann, Kathleen R Nevis, Pingping Qu, et al.
Journal of the National Cancer Institute
|
April 1, 2014
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer
Hanna K Sanoff, Allison M Deal, Janakiraman Krishnamurthy, et al.
Public Health Genomics
|
January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer
N T Brewer, J T Defrank, W K Chiu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
Benjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
British Journal of Clinical Pharmacology
|
April 25, 2015
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
Daniel L Hertz, Anna C Snavely, Howard L McLeod, et al.
The Oncologist
|
May 27, 2016
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Daniel L Hertz, Allison Deal, Joseph G Ibrahim, et al.
Page
of 52